Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143.

被引：49
|
作者：
Reardon, David A.
Sampson, John H.
Sahebjam, Solmaz
Lim, Michael
Baehring, Joachim M.
Vlahovic, Gordana
Cloughesy, Timothy Francis
Strauss, Lewis C.
Latek, Robert Raymond
Paliwal, Prashni
Harbison, Christopher T.
Voloschin, Alfredo Daniel
Omuro, Antonio Marcilio Padula
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.2014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2014
引用
收藏
页数：2
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF NIVOLUMAB (NIVO) AND NIVO IN COMBINATION WITH IPILIMUMAB (IPI) IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN COLOMBIA: ANALYSIS USING 78-MONTH OVERALL SURVIVAL FROM CHECKMATE 067
    Kendall, R.
    Barco, V
    Sharma, A.
    McDonald, L.
    Perlaza, Garcia J.
    Baker, T.
    VALUE IN HEALTH, 2023, 26 (12) : S187 - S187
  • [42] Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.
    Lebbe, Celeste
    Meyer, Nicolas
    Mortier, Laurent
    Marquez-Rodas, Ivan
    Robert, Caroline
    Rutkowski, Piotr
    Butler, Marcus O.
    Eigentler, Thomas
    Menzies, Alexander M.
    Smylie, Michael
    Arance, Ana Maria
    Ascierto, Paolo Antonio
    Svane, Inge Marie
    Ajaz, Mazhar
    Khushalani, Nikhil I.
    Lobo, Maurice
    Zoco, Jesus
    Pigozzo, Jacopo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO plus IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO
    Gutzmer, R.
    Eigentler, T.
    Mohr, P.
    Weichenthal, M.
    Duecker, P.
    Gebhardt, C.
    Goeppner, D.
    Haferkamp, S.
    Kaehler, K.
    Meier, F.
    Pfoehler, C.
    Satzger, I.
    Sickmann, T.
    Sindrilaru, A.
    Terheyden, P.
    Ugurel, S.
    Ulrich, J.
    Utikal, J.
    Weishaupt, C.
    Schadendorf, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S746 - S747
  • [44] Phase 2 study to evaluate efficacy and safety of combination therapy with nivolumab (NIVO) and ipilimumab(IPI) in patients with previously untreated melanoma
    Kiyohara, Y.
    Takenouchi, T.
    Uhara, H.
    Koga, H.
    Uchi, H.
    Yamazaki, N.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean Jacques
    Cowey, Charles Lance
    Lao, Christopher D.
    Schadendorf, Dirk
    Ferrucci, Pier Francesco
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew Graham
    Haanen, John B. A. G.
    Maio, Michele
    McArthur, Grant A.
    Yang, Arvin
    Rollin, Linda
    Horak, Christine E.
    Larkin, James M. G.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.
    Hodi, F. Stephen
    Postow, Michael Andrew
    Chesney, Jason Alan
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth F.
    McDermott, David F.
    Linette, Gerald P.
    Meyer, Nicolas
    Giguere, Jeffrey K.
    Agarwala, Sanjiv S.
    Shaheen, Montaser F.
    Ernstoff, Marc S.
    Minor, David R.
    Salama, April
    Taylor, Matthew Hiram
    Ott, Patrick Alexander
    Horak, Christine E.
    Gagnier, Paul
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Haanen, John B. A. G.
    Espinosa, Enrique
    Demidov, Lev V.
    Garbe, Claus
    Lorigan, Paul
    Gogas, Helen
    Hoeller, Christoph
    Guren, Tormod Kyrre
    Rorive, Andree
    Rutkowski, Piotr
    Munoz-Couselo, Eva
    Dummer, Reinhard
    Carneiro, Ana
    Hospers, Geke
    Grigoryeva, Elena Borisovna
    Bhore, Rafia
    Nathan, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] NIVOLUMAB IN COMBINATION WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE 143
    Omuro, A.
    Vlahovic, G.
    Baehring, J.
    Butowski, N.
    Reardon, D.
    Cloughesy, T.
    Sahebjam, S.
    Lim, M.
    Zwirtes, R.
    Sampson, J.
    NEURO-ONCOLOGY, 2017, 19 : 13 - 13
  • [49] First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW.
    Andre, Thierry
    Elez, Elena
    Lenz, Heinz-Josef
    Jensen, Lars Henrik
    Touchefeu, Yann
    Van Cutsem, Eric
    Garcia-Carbonero, Rocio
    Tougeron, David
    Mendez, Guillermo
    Schenker, Michael
    de la Fouchardiere, Christelle
    Limon, Maria Luisa
    Yoshino, Takayuki
    Li, Jin
    Aubin, Francine
    Cela, Elvis
    Chen, Tian
    Lei, Ming
    Jin, Lixian
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : LBA143 - LBA143
  • [50] Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067)
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean Jacques
    Cowey, Charles Lance
    Lao, Christopher D.
    Schadendorf, Dirk
    Ferrucci, Pier Francesco
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew Graham
    Haanen, John B. A. G.
    Maio, Michele
    McArthur, Grant A.
    Yang, Arvin
    Rollin, Linda
    Horak, Christine E.
    Larkin, James M. G.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
12345